DOCSLIB.ORG

Bioinformatics-Based Prediction of FUT8 As a Therapeutic Target in Estrogen Receptor-Positive Breast Cancer Fateme Shaabanpour Aghamaleki1, Shirin Farivar1,*

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Bioinformatics-Based Prediction of FUT8 As a Therapeutic Target in Estrogen Receptor-Positive Breast Cancer Fateme Shaabanpour Aghamaleki1, Shirin Farivar1,* Multidisciplinary Cancer Investigation Original Article January 2019, Volume 3, Issue 1 Bioinformatics-Based Prediction of FUT8 as a Therapeutic Target in Estrogen Receptor-Positive Breast Cancer Fateme Shaabanpour Aghamaleki1, Shirin Farivar1,* 1 Department of Cellullar-Molecular Biology , Faculty of biological Sciences and technologies, Shahid Beheshti University G.C., Tehran, Iran *Corresponding author: Shirin Farivar,Department of Cellullar-Molecular Biology, Faculty of biological Sciences and technologies, Shahid Beheshti University G.C., Tehran, Iran. Tel: +982129902720; Fax: +982122431664; E-mail: [email protected] DOI: 10.30699/acadpub.mci.3.1.25 Abstract Submitted: 20 October 2018 Introduction: Estrogen receptor-positive (ER-positive) breast cancer is a subgroup of Revised: 4 November 2018 breast tumors that is more likely to respond to hormone therapy. ER-positive and ER- Accepted: 28 November 2018 negative breast cancers tend to show different patterns of metastasis because of different e-Published: 1 January 2019 signaling cascade and genes that are activated by estrogen response. Genetic factors can contribute to high rates of metastasis in ER-positive breast cancer. Fucosyltransferase 8 Keywords: (FUT8) is a member of fucosyltransferases family and plays an important role in α-1,6 Fucosyltransferases linkage to the first GlcNAc residue of N-glycans chain. In this study, for the first time, Breast Neoplasms Microarray Analysis we predicted FUT8 by bioinformatics tools as a novel therapeutic target for ER-positive Signal Transduction breast cancer. Methods: Microarray gene expression data of 9 patients with ER+ve and 10 individuals with ER-ve breast cancer was extracted from Geodatasets. Gene expression of two ER+ and ER- patients was compared with logfc and then sorted by their p-values. Moreover, the most related pathway, protein interaction, and function of this gene were identified with GeneCard and DAVID databases. Results: FUT8 was highly expressed in patients with ER+ve breast cancer that may be associated with the metastasis. FUT8 encodes an enzyme that belongs to fucosyltransferases family. The expression of this gene may contribute to the malignancy features of cancer cells and their invasive and metastatic capabilities. Conclusions: Having in mind FUT8 hyperexpression, its function in malignancy, and its pathways, it can be concluded that FUT8 can be used as a therapeutic target in ER+ve breast cancer. © 2019. Multidisciplinary Cancer Investigation INTRODUCTION Breast cancer is one of the most prevalent receptors, progesterone receptors, and HER2), and malignancies in women with 4 major types according triple negative (these tumors are not positive for to the presence of sex hormone receptors on the estrogen receptors, progesterone receptors, and cancer cell. Endocrine receptor-positive (estrogen HER2) tumors are the main categories of breast or progesterone receptors), HER2-positive, triple cancer [1-3]. About 80% of all breast cancers are positive (these tumors are positive for estrogen estrogen receptor-positive (ER-positive) that may Multidiscip Cancer Invest. January 2019, Volume 3, Issue 1 influence the growth of cancer cells in response ER-ve patients that were submitted in September to the estrogen [4-6]. About 65% of breast tumors 2011 and updated in April 2017. are progesterone receptor-positive (PR-positive) Gene Expression Profile Analysis which grow in response to another sex hormone called progesterone [7-9]. These hormones This profile was analyzed; using limma package in R especially estrogen, play an important role in cell program. Limma is an R/Bioconductor package and cycle and tumor progression [4, 10, 11]. Estrogens a powerful differential expression analyzing tool are considered to play a major role in promoting for RNA-sequencing and microarray studies [20, the proliferation of normal and neoplastic breast 21]. Generated unnormalized data were normalized epithelial cells. Three major mechanisms are by robust multiarray averaging (RMA) method. suggested to be involved in estrogen carcinogenic To determine data value and their normalization, effects: 1. Stimulation of cellular proliferation the distribution of the samples was performed. In through estrogens receptor-mediated hormonal this step, genes were compared based on their log activity. Actually, when hormones bind to the cell fold change (logfc) and their level of expression surface receptors, hormone-responsive genes and between ER+ve and ER-ve breast cancer patients. signaling cascades including MAPK signaling They were then sorted into hyperexpressed genes and PI3K signaling pathways, are turned on for in ER+ve patients and hypoexressed genes in ER- DNA synthesis and cell proliferation. 2. Increasing ve breast cancer individuals according to their mutation level through a cytochrome P450-mediated p-value and vice versa to determine specific gene metabolic activation. Cytochrome P-450 catalyzes in ER+ve breast cancer. Moreover, the expression the oxidative metabolism of estrogen and estradiol level of a gene of interest was determined among to a 2-hydroxycatechol estrogen that can induce all 19 samples through the profile graph in NCBI genetic mutations. 3. Induction of aneuploidy Geodatasets. Finally, a gene that was hyperexpressed including loss of 9p11-13 and 4p15.3-16 deletion and had the lowest p-value in ER+ve breast cancer that have been introduced to be tumorigenic in patients was chosen for further analysis. The most several studies [12-14]. In addition, genetic factors related pathway (Gene Ontology) and function of play an important role in breast cancer initiation the gene of interest were identified by the GeneCard and progression. Among genetics element, somatic and DAVID databases for understanding its effect in mutations happen more frequently in breast cells [15]. the pathogenesis of ER+ breast tumor. However, some patients show a germline mutation in BRCA1 and BRCA2 genes. These genes are used GSE32394/GPL11097,selected sample in many prediction tests for breast cancer in patients with a familial background [16-18]. Some of the important genes are expressed only after activating 12 the estrogen receptor and affect both normal and cancer cells. Therefore, identification of molecular 10 keys in breast cancer can result in better decision making about breast cancer treatment. In this article, 8 Microarray gene expression data of breast cancer patients were studied from Geodatabase to identify 6 critical and different genes between ER-positive and ER-negative breast cancer. 4 METHODS 2 Gene Profile Extraction Microarray gene expression data of 9 cases with ER+ve and 10 patients with ER-ve breast cancer GSM801843 GSM801844 GSM801845 GSM801846 GSM801847 GSM801848 GSM801849 GSM801850 GSM801851 GSM801852 GSM801853 GSM801854 GSM801855 GSM801856 GSM801857 GSM801858 GSM801859 GSM801860 GSM801861 (GSE32394) were extracted from NCBI Geodatasets Figure 1: Distribution of Data Value: Distribution Can Be Viewed by [19]. This profile included samples of ER+ve and Box Plot to Indicate Data Value and Normalization 26 Shaabanpour Aghamaleki et al. motifs. and has SH3_9SH3_1SKI NodZ with 575 aa on14q23.3andencodesaprotein gene islocated gene expression profile analysis (Figure 2).compared toER-vebreast cancerpatientsthrough This with 2.2064logfcinER+vebreastcancerpatients analysis (Figure1).FUT8washyperexpressed expression for gene data microarray a valuable and itsboxplot,itwasconcludedthatcanbe According totheanalysisofdistributeddatavalue RESULTS activity throughSTRINGdatabases. its confirm to identified also was proteins other with of thisgene product of theprotein interaction The 3 Figure Figure 2 Figure Sample value Sample value 10 10 : FUT8 Expression Among All Samples Among : FUT8Expression 5 6 7 8 9 : Different Expression Level of FUT8 Was Observed Among ER+andER-veBreastCancer(GSM IndicatesSamples). Observed Was ExpressionLevelofFUT8 : Different 5 6 7 8 9 expression expression GSM801843 GSM801843 GSM801844 GSM801844 va va lu lu e e GSM801845 GSM801845 GSM801846 ER GSM801846 Positive GSM801847 GSM801847 BC GSE GSM801848 GSE GSM801848 32394/N GSM801849 32394/GPL GSM801849 GSM801850 GSM801850 M_ 178155. GSM801851 11097/NM_ are considered as therapeutic targets forcancer. are consideredastherapeutic targets synthesis pathwayandbiosynthesis ofkeratansulfate N-glycan as EGFR,IGFR,andFGFR. Recently, FUT8, exhibitsinanumber ofglycoproteinssuch and metastasis.N-glycan, which is synthesized by pathway playsanimportantroleincancerinvasion databases(Figure4).N-glycansynthesis and DAVID and transcriptionalmisregulationbasedonGeneCard biosynthesisofkeratansulfate, synthesis pathway, Important pathwaysofFUT8includedN-glycan samples. of the all FUT8 washyperexpressedinnearly that (Figure According 3). to this figure, determined it’s samples all in overexpression its recognize to FUT8 expression was identified among 19 samples GSM801851 GSM801852 GSM801852 1_psr GSM801853 17815 GSM801853 1_ GSM801854 a_at/F GSM801854 5.1 _p GSM801855 UT GSM801855 ER sr 8 1_a_at GSM801856 Ne GSM801856 ga ti ve GSM801857 GSM801857 BC GSM801858 GSM801858 GSM801859 GSM801859 GSM801860 GSM801860 27 GSM801861 GSM801861 Multidiscip Cancer Invest. January 2019, Volume 3, Issue 1 A GLYCOSAMINOGLYCAN BIOSYNTHESIS -KERATAN SULFATE N-Glycan biosynthesis S S S CHST1 CHST6 CHST1 FUcα1 6 6 6 [Gal βı — 4GlcNAcβı]0-40 — [3Gal βı — 4GlcNAcβı]10-12— [3Gal βı — 4GlcNAcβı] — 3Gal βı — 4GlcNAcβı — 2Manα1 FUT8 B4GALT4 B3GNT7 B43ALT4 B3GNT2 B4GALT1,2,3 B3GNT2 B4GALT1,2,3
Load more

Recommended publications
  • Seq2pathway Vignette
    seq2pathway Vignette Bin Wang, Xinan Holly Yang, Arjun Kinstlick May 19, 2021 Contents 1 Abstract 1 2 Package Installation 2 3 runseq2pathway 2 4 Two main functions 3 4.1 seq2gene . .3 4.1.1 seq2gene flowchart . .3 4.1.2 runseq2gene inputs/parameters . .5 4.1.3 runseq2gene outputs . .8 4.2 gene2pathway . 10 4.2.1 gene2pathway flowchart . 11 4.2.2 gene2pathway test inputs/parameters . 11 4.2.3 gene2pathway test outputs . 12 5 Examples 13 5.1 ChIP-seq data analysis . 13 5.1.1 Map ChIP-seq enriched peaks to genes using runseq2gene .................... 13 5.1.2 Discover enriched GO terms using gene2pathway_test with gene scores . 15 5.1.3 Discover enriched GO terms using Fisher's Exact test without gene scores . 17 5.1.4 Add description for genes . 20 5.2 RNA-seq data analysis . 20 6 R environment session 23 1 Abstract Seq2pathway is a novel computational tool to analyze functional gene-sets (including signaling pathways) using variable next-generation sequencing data[1]. Integral to this tool are the \seq2gene" and \gene2pathway" components in series that infer a quantitative pathway-level profile for each sample. The seq2gene function assigns phenotype-associated significance of genomic regions to gene-level scores, where the significance could be p-values of SNPs or point mutations, protein-binding affinity, or transcriptional expression level. The seq2gene function has the feasibility to assign non-exon regions to a range of neighboring genes besides the nearest one, thus facilitating the study of functional non-coding elements[2]. Then the gene2pathway summarizes gene-level measurements to pathway-level scores, comparing the quantity of significance for gene members within a pathway with those outside a pathway.
    [Show full text]
  • Whole Exome Sequencing in ADHD Trios from Single and Multi-Incident Families Implicates New Candidate Genes and Highlights Polygenic Transmission
    European Journal of Human Genetics (2020) 28:1098–1110 https://doi.org/10.1038/s41431-020-0619-7 ARTICLE Whole exome sequencing in ADHD trios from single and multi-incident families implicates new candidate genes and highlights polygenic transmission 1,2 1 1,2 1,3 1 Bashayer R. Al-Mubarak ● Aisha Omar ● Batoul Baz ● Basma Al-Abdulaziz ● Amna I. Magrashi ● 1,2 2 2,4 2,4,5 6 Eman Al-Yemni ● Amjad Jabaan ● Dorota Monies ● Mohamed Abouelhoda ● Dejene Abebe ● 7 1,2 Mohammad Ghaziuddin ● Nada A. Al-Tassan Received: 26 September 2019 / Revised: 26 February 2020 / Accepted: 10 March 2020 / Published online: 1 April 2020 © The Author(s) 2020. This article is published with open access Abstract Several types of genetic alterations occurring at numerous loci have been described in attention deficit hyperactivity disorder (ADHD). However, the role of rare single nucleotide variants (SNVs) remains under investigated. Here, we sought to identify rare SNVs with predicted deleterious effect that may contribute to ADHD risk. We chose to study ADHD families (including multi-incident) from a population with a high rate of consanguinity in which genetic risk factors tend to 1234567890();,: 1234567890();,: accumulate and therefore increasing the chance of detecting risk alleles. We employed whole exome sequencing (WES) to interrogate the entire coding region of 16 trios with ADHD. We also performed enrichment analysis on our final list of genes to identify the overrepresented biological processes. A total of 32 rare variants with predicted damaging effect were identified in 31 genes. At least two variants were detected per proband, most of which were not exclusive to the affected individuals.
    [Show full text]
  • Yeast Genome Gazetteer P35-65
    gazetteer Metabolism 35 tRNA modification mitochondrial transport amino-acid metabolism other tRNA-transcription activities vesicular transport (Golgi network, etc.) nitrogen and sulphur metabolism mRNA synthesis peroxisomal transport nucleotide metabolism mRNA processing (splicing) vacuolar transport phosphate metabolism mRNA processing (5’-end, 3’-end processing extracellular transport carbohydrate metabolism and mRNA degradation) cellular import lipid, fatty-acid and sterol metabolism other mRNA-transcription activities other intracellular-transport activities biosynthesis of vitamins, cofactors and RNA transport prosthetic groups other transcription activities Cellular organization and biogenesis 54 ionic homeostasis organization and biogenesis of cell wall and Protein synthesis 48 plasma membrane Energy 40 ribosomal proteins organization and biogenesis of glycolysis translation (initiation,elongation and cytoskeleton gluconeogenesis termination) organization and biogenesis of endoplasmic pentose-phosphate pathway translational control reticulum and Golgi tricarboxylic-acid pathway tRNA synthetases organization and biogenesis of chromosome respiration other protein-synthesis activities structure fermentation mitochondrial organization and biogenesis metabolism of energy reserves (glycogen Protein destination 49 peroxisomal organization and biogenesis and trehalose) protein folding and stabilization endosomal organization and biogenesis other energy-generation activities protein targeting, sorting and translocation vacuolar and lysosomal
    [Show full text]
  • Congenital Disorders of Glycosylation from a Neurological Perspective
    brain sciences Review Congenital Disorders of Glycosylation from a Neurological Perspective Justyna Paprocka 1,* , Aleksandra Jezela-Stanek 2 , Anna Tylki-Szyma´nska 3 and Stephanie Grunewald 4 1 Department of Pediatric Neurology, Faculty of Medical Science in Katowice, Medical University of Silesia, 40-752 Katowice, Poland 2 Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland; [email protected] 3 Department of Pediatrics, Nutrition and Metabolic Diseases, The Children’s Memorial Health Institute, W 04-730 Warsaw, Poland; [email protected] 4 NIHR Biomedical Research Center (BRC), Metabolic Unit, Great Ormond Street Hospital and Institute of Child Health, University College London, London SE1 9RT, UK; [email protected] * Correspondence: [email protected]; Tel.: +48-606-415-888 Abstract: Most plasma proteins, cell membrane proteins and other proteins are glycoproteins with sugar chains attached to the polypeptide-glycans. Glycosylation is the main element of the post- translational transformation of most human proteins. Since glycosylation processes are necessary for many different biological processes, patients present a diverse spectrum of phenotypes and severity of symptoms. The most frequently observed neurological symptoms in congenital disorders of glycosylation (CDG) are: epilepsy, intellectual disability, myopathies, neuropathies and stroke-like episodes. Epilepsy is seen in many CDG subtypes and particularly present in the case of mutations
    [Show full text]
  • Supplementary Table 2 Gene Sets Used in GSEA
    Supplementary Table 2 Gene sets used in GSEA Up in RNAi and Sign Confirmed in Inducible Gene Probe Set ID Accession Symbol Gene Title 200660_at NM_005620 S100A11 S100 calcium binding protein A11 (calgizzarin) 200785_s_at NM_002332 LRP1 low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor) 201325_s_at NM_001423 EMP1 epithelial membrane protein 1 201373_at NM_000445 PLEC1 plectin 1, intermediate filament binding protein 500kDa 201466_s_at NM_002228 JUN v-jun sarcoma virus 17 oncogene homolog (avian) 201952_at AA156721 ALCAM activated leukocyte cell adhesion molecule 202042_at NM_002109 HARS histidyl-tRNA synthetase 202074_s_at NM_021980 OPTN optineurin 202087_s_at NM_001912 CTSL cathepsin L 202588_at NM_000476 AK1 adenylate kinase 1 202609_at NM_004447 EPS8 epidermal growth factor receptor pathway substrate 8 202733_at NM_004199 P4HA2 procollagen-proline, 2-oxoglutarate 4-dioxygenase (proline 4-hydroxylase), alpha polypeptide II 202756_s_at NM_002081 GPC1 glypican 1 202786_at NM_013233 STK39 serine threonine kinase 39 (STE20/SPS1 homolog, yeast) 202859_x_at NM_000584 IL8 interleukin 8 203083_at NM_003247 THBS2 thrombospondin 2 203186_s_at NM_002961 S100A4 S100 calcium binding protein A4 (calcium protein, calvasculin, metastasin, murine placental homolog) 203232_s_at NM_000332 ATXN1 ataxin 1 203233_at NM_000418 IL4R interleukin 4 receptor 203771_s_at AA740186 BLVRA biliverdin reductase A 203821_at NM_001945 HBEGF heparin-binding EGF-like growth factor 203939_at NM_002526 NT5E 5'-nucleotidase, ecto (CD73) 203955_at NM_014811
    [Show full text]
  • Download Validation Data
    PrimePCR™Assay Validation Report Gene Information Gene Name UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 4 Gene Symbol B4GALT4 Organism Human Gene Summary This gene is one of seven beta-14-galactosyltransferase (beta4GalT) genes. They encode type II membrane-bound glycoproteins that appear to have exclusive specificity for the donor substrate UDP-galactose; all transfer galactose in a beta14 linkage to similar acceptor sugars: GlcNAc Glc and Xyl. Each beta4GalT has a distinct function in the biosynthesis of different glycoconjugates and saccharide structures. As type II membrane proteins they have an N-terminal hydrophobic signal sequence that directs the protein to the Golgi apparatus and which then remains uncleaved to function as a transmembrane anchor. By sequence similarity the beta4GalTs form four groups: beta4GalT1 and beta4GalT2 beta4GalT3 and beta4GalT4 beta4GalT5 and beta4GalT6 and beta4GalT7. The enzyme encoded by this gene appears to mainly play a role in glycolipid biosynthesis. Two alternatively spliced transcript variants have been found for this gene. Gene Aliases B4Gal-T4, beta4Gal-T4 RefSeq Accession No. NC_000003.11, NT_005612.16 UniGene ID Hs.13225 Ensembl Gene ID ENSG00000121578 Entrez Gene ID 8702 Assay Information Unique Assay ID qHsaCED0001445 Assay Type SYBR® Green Detected Coding Transcript(s) ENST00000483209, ENST00000467604, ENST00000471675, ENST00000359213, ENST00000393765, ENST00000475803, ENST00000479150 Amplicon Context Sequence TGAGGTAAGGAGACACAGAAGGGCAGTTGTCAAGTTCTACCTTCTTCGTGGATG CTTCATTAGTCAGAGTTTTTCCCTTCCCCAAAATGAGGGT Amplicon Length (bp) 64 Chromosome Location 3:118948694-118948787 Assay Design Exonic Purification Desalted Validation Results Efficiency (%) 103 Page 1/5 PrimePCR™Assay Validation Report R2 0.9998 cDNA Cq 21.23 cDNA Tm (Celsius) 78 gDNA Cq 23.9 Specificity (%) 100 Information to assist with data interpretation is provided at the end of this report.
    [Show full text]
  • NUTM1 Is a Recurrent Fusion Gene Partner in B-Cell Precursor Acute
    LETTERS TO THE EDITOR However, 20-25% of BCP-ALL patients do not have one NUTM1 is a recurrent fusion gene partner in B-cell of these sentinel cytogenetic aberrations and are there- precursor acute lymphoblastic leukemia associated fore said to have B-other ALL. This B-other ALL subgroup with increased expression of genes on chromosome has an intermediate risk of relapse, but includes both band 10p12.31-12.2 high- and low-risk subgroups that are currently being identified. Our laboratory identified a subtype with a For 20-25% of patients with pediatric B-cell precursor similar expression profile and prognosis as BCR-ABL1, acute lymphoblastic leukemia (BCP-ALL), the driving namely BCR-ABL1-like, within the B-other ALL sub- cytogenetic aberration is unknown. Identification of the group.2 The B-other ALL subgroup also includes other primary lesion could provide better risk stratification and rare cytogenetic subtypes, such as intrachromosomal even identify possible treatment options. We therefore amplification of chromosome 21 and a dicentric chromo- aimed to find novel recurrent genetic aberrations in BCP- 1 ALL cases. We identified an in-frame SLC12A6-NUTM1 some (9;20). It is important to identify more primary fusion, resulting in expression of 3’ exons of NUTM1, lesions in the remaining B-other ALL for better risk strat- and six additional NUTM1-rearranged fusion cases. ification and identification of possible treatment options. These NUTM1-rearranged cases were associated with In this study, we aimed to identify recurrent fusions in high expression of a cluster of genes on chromosome BCP-ALL cases without currently known lesions through band 10p12.31-12.2, including the BMI1 gene.
    [Show full text]
  • Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
    Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase
    [Show full text]
  • Molecular Diagnostic Requisition
    BAYLOR MIRACA GENETICS LABORATORIES SHIP TO: Baylor Miraca Genetics Laboratories 2450 Holcombe, Grand Blvd. -Receiving Dock PHONE: 800-411-GENE | FAX: 713-798-2787 | www.bmgl.com Houston, TX 77021-2024 Phone: 713-798-6555 MOLECULAR DIAGNOSTIC REQUISITION PATIENT INFORMATION SAMPLE INFORMATION NAME: DATE OF COLLECTION: / / LAST NAME FIRST NAME MI MM DD YY HOSPITAL#: ACCESSION#: DATE OF BIRTH: / / GENDER (Please select one): FEMALE MALE MM DD YY SAMPLE TYPE (Please select one): ETHNIC BACKGROUND (Select all that apply): UNKNOWN BLOOD AFRICAN AMERICAN CORD BLOOD ASIAN SKELETAL MUSCLE ASHKENAZIC JEWISH MUSCLE EUROPEAN CAUCASIAN -OR- DNA (Specify Source): HISPANIC NATIVE AMERICAN INDIAN PLACE PATIENT STICKER HERE OTHER JEWISH OTHER (Specify): OTHER (Please specify): REPORTING INFORMATION ADDITIONAL PROFESSIONAL REPORT RECIPIENTS PHYSICIAN: NAME: INSTITUTION: PHONE: FAX: PHONE: FAX: NAME: EMAIL (INTERNATIONAL CLIENT REQUIREMENT): PHONE: FAX: INDICATION FOR STUDY SYMPTOMATIC (Summarize below.): *FAMILIAL MUTATION/VARIANT ANALYSIS: COMPLETE ALL FIELDS BELOW AND ATTACH THE PROBAND'S REPORT. GENE NAME: ASYMPTOMATIC/POSITIVE FAMILY HISTORY: (ATTACH FAMILY HISTORY) MUTATION/UNCLASSIFIED VARIANT: RELATIONSHIP TO PROBAND: THIS INDIVIDUAL IS CURRENTLY: SYMPTOMATIC ASYMPTOMATIC *If family mutation is known, complete the FAMILIAL MUTATION/ VARIANT ANALYSIS section. NAME OF PROBAND: ASYMPTOMATIC/POPULATION SCREENING RELATIONSHIP TO PROBAND: OTHER (Specify clinical findings below): BMGL LAB#: A COPY OF ORIGINAL RESULTS ATTACHED IF PROBAND TESTING WAS PERFORMED AT ANOTHER LAB, CALL TO DISCUSS PRIOR TO SENDING SAMPLE. A POSITIVE CONTROL MAY BE REQUIRED IN SOME CASES. REQUIRED: NEW YORK STATE PHYSICIAN SIGNATURE OF CONSENT I certify that the patient specified above and/or their legal guardian has been informed of the benefits, risks, and limitations of the laboratory test(s) requested.
    [Show full text]
  • Viewed and Published Immediately Upon Acceptance Cited in Pubmed and Archived on Pubmed Central Yours — You Keep the Copyright
    BMC Genomics BioMed Central Research article Open Access Differential gene expression in ADAM10 and mutant ADAM10 transgenic mice Claudia Prinzen1, Dietrich Trümbach2, Wolfgang Wurst2, Kristina Endres1, Rolf Postina1 and Falk Fahrenholz*1 Address: 1Johannes Gutenberg-University, Institute of Biochemistry, Mainz, Johann-Joachim-Becherweg 30, 55128 Mainz, Germany and 2Helmholtz Zentrum München – German Research Center for Environmental Health, Institute for Developmental Genetics, Ingolstädter Landstraße 1, 85764 Neuherberg, Germany Email: Claudia Prinzen - [email protected]; Dietrich Trümbach - [email protected]; Wolfgang Wurst - [email protected]; Kristina Endres - [email protected]; Rolf Postina - [email protected]; Falk Fahrenholz* - [email protected] * Corresponding author Published: 5 February 2009 Received: 19 June 2008 Accepted: 5 February 2009 BMC Genomics 2009, 10:66 doi:10.1186/1471-2164-10-66 This article is available from: http://www.biomedcentral.com/1471-2164/10/66 © 2009 Prinzen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Abstract Background: In a transgenic mouse model of Alzheimer disease (AD), cleavage of the amyloid precursor protein (APP) by the α-secretase ADAM10 prevented amyloid plaque formation, and alleviated cognitive deficits. Furthermore, ADAM10 overexpression increased the cortical synaptogenesis. These results suggest that upregulation of ADAM10 in the brain has beneficial effects on AD pathology. Results: To assess the influence of ADAM10 on the gene expression profile in the brain, we performed a microarray analysis using RNA isolated from brains of five months old mice overexpressing either the α-secretase ADAM10, or a dominant-negative mutant (dn) of this enzyme.
    [Show full text]
  • ALG6-CDG in South Africa: Genotype-Phenotype Description of Five Novel Patients
    JIMD Reports DOI 10.1007/8904_2012_150 CASE REPORT ALG6-CDG in South Africa: Genotype-Phenotype Description of Five Novel Patients M. Dercksen • A. C. Crutchley • E. M. Honey • M. M. Lippert • G. Matthijs • L. J. Mienie • H. C. Schuman • B. C. Vorster • J. Jaeken Received: 11 October 2011 /Revised: 30 April 2012 /Accepted: 07 May 2012 # SSIEM and Springer-Verlag Berlin Heidelberg 2012 Abstract ALG6-CDG (formerly named CDG-Ic) (pheno- for the known c.998C>T (p.A333V) mutation and the novel type OMIM 603147, genotype OMIM 604566), is caused by c.1338dupA (p.V447SfsX44) mutation. Four more patients, defective endoplasmic reticulum a-1,3-glucosyltransferase presenting with classical neurological involvement were (E.C 2.4.1.267) in the N-glycan assembly pathway identified and were compound heterozygous for the known (Grunewald€ et al. 2000). It is the second most frequent c.257 + 5G>A splice mutation and the c.680G>A(p.G227E) N-glycosylation disorder after PMM2-CDG; some 37 patients missense mutation. The patients belong to a semi-isolated have been reported with 21 different ALG6 gene mutations Caucasian community that may have originated from Euro- (Haeuptle & Hennet 2009; Al-Owain 2010). We report on the pean pioneers who colonized South Africa in the seventeenth/ clinical and biochemical findings of five novel Caucasian eighteenth centuries. South African patients. The first patient had a severe neuro- gastrointestinal presentation. He was compound heterozygous Introduction Communicated by: Eva Morava, MD PhD ALG6-CG (phenotype OMIM 603147, genotype OMIM Competing interests: none declared : : 604566) is a genetic disorder in the assembly of N-glycans M.
    [Show full text]
  • Viruses Like Sugars: How to Assess Glycan Involvement in Viral Attachment
    microorganisms Review Viruses Like Sugars: How to Assess Glycan Involvement in Viral Attachment Gregory Mathez and Valeria Cagno * Institute of Microbiology, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland; [email protected] * Correspondence: [email protected] Abstract: The first step of viral infection requires interaction with the host cell. Before finding the specific receptor that triggers entry, the majority of viruses interact with the glycocalyx. Identifying the carbohydrates that are specifically recognized by different viruses is important both for assessing the cellular tropism and for identifying new antiviral targets. Advances in the tools available for studying glycan–protein interactions have made it possible to identify them more rapidly; however, it is important to recognize the limitations of these methods in order to draw relevant conclusions. Here, we review different techniques: genetic screening, glycan arrays, enzymatic and pharmacological approaches, and surface plasmon resonance. We then detail the glycan interactions of enterovirus D68 and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), highlighting the aspects that need further clarification. Keywords: attachment receptor; viruses; glycan; sialic acid; heparan sulfate; HBGA; SARS-CoV-2; EV-D68 Citation: Mathez, G.; Cagno, V. Viruses Like Sugars: How to Assess 1. Introduction Glycan Involvement in Viral This review focuses on methods for assessing the involvement of carbohydrates in Attachment. Microorganisms 2021, 9, viral attachment and entry into the host cell. Viruses often bind to entry receptors that are 1238. https://doi.org/10.3390/ not abundant on the cell surface; to increase their chances of finding them, they initially microorganisms9061238 bind to attachment receptors comprising carbohydrates that are more widely expressed.
    [Show full text]